We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Lipidoid Technique Allows Simultaneous Silencing of Multiple Genes

By LabMedica International staff writers
Posted on 18 Jan 2010
A recent paper described the development of a novel transport system that should potentiate the therapeutic use of RNA interference (siRNA) technology by overcoming the current difficulties in delivering the gene silencing molecules to target cells.

Investigators at the Massachusetts Institute of Technology (MIT; Cambridge, MA, USA) and Alnylam Pharmaceuticals (Cambridge, MA, USA) developed a novel siRNA delivery system based on fat-like molecules called lipidoids. More...
Complexes of lipidoid-coated siRNA particles were found to readily penetrate the lipid membrane of target tissues.

In the current study, published in the January 11, 2010, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences (PNAS), siRNA-lipoid complexes containing up to five separate and specific siRNA moieties were delivered to liver cells in mice and nonhuman primates. Results showed that this formulation enabled liver gene silencing in mice at doses below 0.01 mg/kg. Furthermore, it specifically inhibited expression of five hepatic genes simultaneously, after a single injection. The potential of this formulation was further validated in nonhuman primates, where high levels of knockdown of the clinically relevant gene transthyretin were observed at doses as low as 0.03 mg/kg. According to the authors, effective gene silencing was obtained at orders-of-magnitude lower doses than required by any previously described siRNA liver delivery system.

"This greatly improved efficacy allows us to dramatically decrease the dose levels, and also opens the door to formulations that can simultaneously inhibit multiple genes or pathways," said senior author Dr. Daniel G Anderson, professor of biomedical engineering at MIT.

Related Links:
Massachusetts Institute of Technology
Alnylam Pharmaceuticals


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
H-FABP Assay
Heart-Type Fatty Acid-Binding Protein Assay
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Nian Sun has spent years perfecting a device that he believes could change the way diseases are detected. (Photo courtesy of Alyssa Stone/Northeastern University)

Rapid Breath Sensor Detects SARS-CoV-2 from Exhaled Air

Nasal swabs and polymerase chain reaction (PCR) testing have been central to identifying SARS-CoV-2, but they can be uncomfortable, slow, and logistically complex when samples require transport.... Read more

Molecular Diagnostics

view channel
Image: At the MHH Institute of Human Genetics: Prof. Dr. Doris Steinemann, Dr. Bernardus Aldrige Allister and Prof. Dr Monika Golas (from left). (Image Credit: Karin Kaiser/MHH)

Multi-Omics Analysis Identifies Additional Risk Genes in Hereditary Breast and Ovarian Cancer

Hereditary breast and ovarian cancer can be difficult to explain genetically, leaving many high-risk families without clear answers. Although 13 established risk genes, including BRCA1 and BRCA2, are routinely... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.